After this article [1] was published, concerns were raised regarding results presented in Figs 2, 3, 5 and 6. Specifically,
- In the cleaved CPP32 panel in Fig 3C, the upper and lower bands in lanes 5-8 appear similar to each other.
- In the Cleaved CPP32 panel in Fig 5F, the bands in lanes 2 and 3 appear similar to each other.
- Lanes 1-4 in the Fig 6A cytosol mitochondrial marker panel appear similar to lanes 1-4 in the Fig 6A mitochondria β-tubulin panel.
- The following western blot panels appear similar to each other:
- Fig 3F β tubulin and Fig 5D actin
- Fig 3A IGROV-1 mitochondrial extract mit. marker and Fig 3A IGROV-1/Pt1 CPP32
- Fig 3E actin and Fig 5E actin
- Fig 3C β tubulin and Fig 5G actin
- Fig 3A IGROV-1/Pt1 actin and Fig 5C actin
- There appear to be vertical discontinuities in several panels in Figs 2, 3, 5 and 6.
The authors did not respond to the editorial request for comment on these concerns.
In light of the above concerns, which call into question the integrity and reliability of [1], the PLOS One Editors retract this article.
All authors either did not respond directly or could not be reached.
Reference
Citation: The PLOS One Editors (2026) Retraction: Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo. PLoS One 21(3): e0344841. https://doi.org/10.1371/journal.pone.0344841
Published: March 16, 2026
Copyright: © 2026 The PLOS One Editors. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.